Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 381

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

Fishbane, Steven, Jamal, Aamir, Munera, Catherine, Wen, Warren, Menzaghi, Frédérique·2020·New England Journal of Medicine

Abstract

BACKGROUND: Difelikefalin is a peripherally restricted and selective agonist of kappa opioid receptors that are considered to be important in modulating pruritus in conditions such as chronic kidney disease. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients undergoing hemodialysis who had moderate-to-severe pruritus to receive either intravenous difelikefalin (at a dose of 0.5 μg per kilogram of body weight) or placebo three times per week for 12 weeks. The primary outcome was the percentage of patients with an improvement (decrease) of at least 3 points from baseline at week 12 in the weekly mean score on the 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS; scores range from 0 to 10, with higher scores indicating greater itch intensity). The secondary outcomes included the change from baseline in itch-related quality-of-life measures, the percentage of patients with an improvement of at least 4 points in the WI-NRS score at week 12, and safety. RESULTS: A total of 378 patients underwent randomization. A total of 82 of 158 patients (51.9%) in the difelikefalin group had a decrease of at least 3 points in the WI-NRS score (primary outcome), as compared with 51 of 165 (30.9%) in the placebo group. The imputed percentage of patients with a decrease of at least 3 points in the WI-NRS score was 49.1% in the difelikefalin group, as compared with 27.9% in the placebo group (P<0.001). Difelikefalin also resulted in a significant improvement from baseline to week 12 in itch-related quality of life as measured by the 5-D itch scale and the Skindex-10 scale. The imputed percentage of patients with a decrease of at least 4 points in the WI-NRS score at week 12 was significantly greater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of 158 patients] vs. 17.9% [observed data: 35 of 165 patients], P<0.001). Diarrhea, dizziness, and vomiting were more common in the difelikefalin group than in the placebo group. CONCLUSIONS: Patients treated with difelikefalin had a significant reduction in itch intensity and improved itch-related quality of life as compared with those who received placebo. (Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1912770

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 9

  1. 10.2215/CJN.03280317 · doi:10.2215/cjn.03280317
  2. 10.1111/hdi.12158 · doi:10.1111/hdi.12158
  3. 10.1093/ndt/gfi204 · doi:10.1093/ndt/gfi204
  4. Bigliardi PL Bigliardi-Qi M. Peripheral opioids. In: Carstens E Akiyama T eds. Itch: mechanisms and treatment. Boca Raton FL: CRC Press/Taylor & Francis 2014 (https://www.ncbi.nlm.nih.gov/books/NBK200922/).
  5. 10.1016/j.jpain.2015.01.341 · doi:10.1016/j.jpain.2015.01.341
  6. 10.1002/bimj.200390001 · doi:10.1002/bimj.200390001
  7. 10.1111/bjd.14464 · doi:10.1111/bjd.14464
  8. 10.1016/j.jpain.2015.01.340 · doi:10.1016/j.jpain.2015.01.340
  9. Butelman ER, Kreek MJ. Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol 2015;6:190-190.26441647

Cited by

See all 381

Metadata

Authors
Fishbane, S., Jamal, A., Munera, C., Wen, W., & Menzaghi, F.
Venue
New England Journal of Medicine
Published
2020-01-16
Volume
382
Issue
3
Pages
222-232
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2988468898
Cited by
381
References
20
FWCI
28.56
Type
journal article
Language
en
Open access
closed
Funders
Cara Therapeutics, Inc.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. https://app.cochat.ai/papers/10.1056/nejmoa1912770
The paper
Fishbane, S., Jamal, A., Munera, C., Wen, W., & Menzaghi, F. (2020). A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1912770

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.